Literature DB >> 24777253

Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.

Luca Cindolo1, Mario Alvarez-Maestro, Roberto Castellucci, Luigi Schips.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24777253     DOI： 10.1007/s00345-014-1300-y

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  9 in total

1.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

Authors:  Bodil Als-Nielsen; Wendong Chen; Christian Gluud; Lise L Kjaergard
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

Review 2.  Administrative record linkage as a tool for public health research.

Authors:  Douglas P Jutte; Leslie L Roos; Marni D Brownell
Journal:  Annu Rev Public Health       Date:  2011       Impact factor: 21.981

Review 3.  Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.

Authors:  Taehwan Park; Jae-Young Choi
Journal:  World J Urol       Date:  2014-02-06       Impact factor: 4.226

4.  The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.

Authors:  Luca Cindolo; Caterina Fanizza; Marilena Romero; Luisella Pirozzi; Riccardo Autorino; Francesco Berardinelli; Luigi Schips
Journal:  World J Urol       Date:  2012-12-14       Impact factor: 4.226

5.  Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.

Authors:  Luca Cindolo; Francesco Berardinelli; Caterina Fanizza; Marilena Romero; Luisella Pirozzi; Fabiola Raffaella Tamburro; Fabrizio Pellegrini; Fabio Neri; Andrea Pitrelli; Luigi Schips
Journal:  Arch Ital Urol Androl       Date:  2013-12-31

6.  Using routine data to complement and enhance the results of randomised controlled trials.

Authors:  J D Lewsey; A H Leyland; G D Murray; F A Boddy
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

7.  Finasteride versus dutasteride: a real-world economic evaluation.

Authors:  Thomas C Fenter; M Chris Runken; Libby Black; Michael Eaddy
Journal:  Am J Manag Care       Date:  2007-02       Impact factor: 2.229

8.  Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.

Authors:  Thomas C Fenter; E Anne Davis; Manan B Shah; Pei-Jung Lin
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

9.  Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.

Authors:  Michael Naslund; Michael T Eaddy; Eric J Kruep; Susan L Hogue
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229
  9 in total
  2 in total

1.  Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.

Authors:  Hee Joon Bae; Omar Mian; Dhananjay Vaidya; Theodore L DeWeese; Daniel Y Song
Journal:  Pract Radiat Oncol       Date:  2017-10-10

2.  Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.

Authors:  Hye-Yoon Lee; Jong-Kil Nam; Sang-Don Lee; Dong-Hoon Lee; Ji-Yeon Han; Young-Ju Yun; Ji-Hye Lee; Hye-Lim Park; Seong-Ha Park; Jung-Nam Kwon
Journal:  BMJ Open       Date:  2015-12-11       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.